Andrew has 18 years of experience in the pharmaceutical industry with Eli Lilly & Co. He was initially responsible for clinical development and registration of new molecules, principally in relation to neurological and psychiatric disorders and subsequently managed both clinical and preclinical discovery organisations, across multiple therapeutic areas, in Europe and in Asia.
Latterly, Andrew was leader of Eli Lilly’s in-licensing and business development organisation in Europe. Within this role, he had responsibility for evaluating drug and technology development projects and for structuring collaborations with external partners in the biotechnology sector and in academia.
Andrew retired from Eli Lilly in February 2010, since when he has worked as an independent consultant to the pharmaceutical and biotech sectors. He currently sits on company boards and SABs and is a member of the Wellcome Trust TechnologyTransfer Strategy Panel.
Andrew graduated in Natural Sciences (Cambridge University) and Clinical Medicine (Oxford University Medical School) and spent 10 years in academic medicine before entering the pharmaceutical industry.